Research programme: gonadotrophin releasing hormone antagonists - AbbVie/Neurocrine

Drug Profile

Research programme: gonadotrophin releasing hormone antagonists - AbbVie/Neurocrine

Alternative Names: GnRH antagonists - Neurocrine Biosciences

Latest Information Update: 05 Feb 2013

Price : $50

At a glance

  • Originator Neurocrine Biosciences
  • Developer AbbVie; Neurocrine Biosciences
  • Class Diamines
  • Mechanism of Action Gonadotropin releasing hormone inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Cancer
  • No development reported Benign prostatic hyperplasia

Most Recent Events

  • 05 Feb 2013 Preclinical development is ongoing for Cancer in the USA
  • 02 Jan 2013 Abbott separates its pharmaceuticals business to a new company called AbbVie
  • 22 Feb 2011 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top